A dose-response analysis of lenograstim plus dexamethasone for neutrophil mobilization and collection
- 1 April 2005
- journal article
- clinical trial
- Published by Wiley in Transfusion
- Vol. 45 (4) , 604-612
- https://doi.org/10.1111/j.0041-1132.2005.04240.x
Abstract
The objective was to evaluate the dose-response relationship of lenograstim plus dexamethasone for neutrophil mobilization and collection. In a prospective study, 260 healthy volunteers received oral dexamethasone (8 mg) plus a single subcutaneous injection of glycosylated granulocyte-colony-stimulating factor (G-CSF; lenograstim) at medians of 1.5 (1.0-2.3) microg per kg (n = 43), 3 (2.4-4.1) microg per kg (n = 73), 6 (4.3-7.9) microg per kg (n = 123), and 12 (8.2-17.2) microg per kg (n = 21) and underwent neutrophil collections with a polymorphonucleated neutrophil (PMN) program. White blood cell (WBC) counts and PMN mobilization and collection results were compared, and the severity and clinical significance of donor adverse reactions were evaluated. Fifty-two neutropenic patients (29 children, 23 adults) underwent 271 neutrophil transfusions (GTXs) every other day to maintain WBC levels continuously above 0.5 x 10(9) per L. Within the dose range 1.5, 3, and 6 microg per kg, each doubling step was associated with a 10 to 15 percent PMN increase in peripheral blood up to 32.8 (19.1-49.2) x 10(9) per L (6 microg/kg; p </= 0.00032) as well as in the neutrophil concentrate up to 79 (34-150) x 10(9) per U (6 microg/kg; p </= 0.00042). A further doubling to 12 microg per kg achieved neither better mobilization nor better apheresis results. The rate of clinically important adverse reactions increased already with the 6 microg per kg mobilization step. The GTX resulted in median peak WBC increments to 3.8 (0.4-18.2) x 10(9) per L (children) and 1.6 (0.3-9.4) x 10(9) per L (adults), but in adults the WBC threshold of 0.5 x 10(9) per L was not continuously exceeded. The most effective dose-response ratio for PMN mobilization was demonstrated in the 6 microg per kg lenograstim group. In neutropenic adults, GTX treatment on an every-other-day schedule may be ineffective.Keywords
This publication has 29 references indexed in Scilit:
- A comparative study of adverse reactions occurring after administration of glycosylated granulocyte colony stimulating factor and/or dexamethasone for mobilization of neutrophils in healthy donorsAnnals of Hematology, 2004
- Collection of two consecutive neutrophil concentrates for transfusion from donors mobilized with glycosylated granulocyte-CSF plus dexamethasoneTransfusion, 2004
- Is it time for a new look at granulocyte transfusions?Transfusion, 2002
- Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G–CSF (3 μg/kg) plus dexamethasone versus glycosylated G–CSF (12 μg/kg) aloneTransfusion, 2002
- Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF aloneTransfusion, 2001
- Crossover study of the haematological effects and pharmacokinetics of glycosylated and non‐glycosylated G‐CSF in healthy volunteersBritish Journal of Haematology, 1997
- Effects of in vivo administration of G–CSF on neutrophil functions in healthy volunteersEuropean Journal of Haematology, 1997
- A comparative trial of granulocyte‐colony‐stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteersTransfusion, 1997
- Structural Characterization of Natural and Recombinant Human Granulocyte Colony-Stimulating Factors1The Journal of Biochemistry, 1990
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966